Copyright Reports & Markets. All rights reserved.

Global Retinal Biosimilars Market Size, Status and Forecast 2021-2027

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Market Analysis by Type
    • 1.2.1 Global Retinal Biosimilars Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
    • 1.2.2 Macular Degeneration Drugs
    • 1.2.3 Diabetic Eye Disease Drugs
    • 1.2.4 Macular Pucker Drugs
    • 1.2.5 Others
  • 1.3 Market by Application
    • 1.3.1 Global Retinal Biosimilars Market Share by Application: 2016 VS 2021 VS 2027
    • 1.3.2 Hospital Pharmacies
    • 1.3.3 Retail Pharmacies
    • 1.3.4 Online Pharmacies
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Global Growth Trends

  • 2.1 Global Retinal Biosimilars Market Perspective (2016-2027)
  • 2.2 Retinal Biosimilars Growth Trends by Regions
    • 2.2.1 Retinal Biosimilars Market Size by Regions: 2016 VS 2021 VS 2027
    • 2.2.2 Retinal Biosimilars Historic Market Share by Regions (2016-2021)
    • 2.2.3 Retinal Biosimilars Forecasted Market Size by Regions (2022-2027)
  • 2.3 Retinal Biosimilars Industry Dynamic
    • 2.3.1 Retinal Biosimilars Market Trends
    • 2.3.2 Retinal Biosimilars Market Drivers
    • 2.3.3 Retinal Biosimilars Market Challenges
    • 2.3.4 Retinal Biosimilars Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top Retinal Biosimilars Players by Revenue
    • 3.1.1 Global Top Retinal Biosimilars Players by Revenue (2016-2021)
    • 3.1.2 Global Retinal Biosimilars Revenue Market Share by Players (2016-2021)
  • 3.2 Global Retinal Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Players Covered: Ranking by Retinal Biosimilars Revenue
  • 3.4 Global Retinal Biosimilars Market Concentration Ratio
    • 3.4.1 Global Retinal Biosimilars Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by Retinal Biosimilars Revenue in 2020
  • 3.5 Retinal Biosimilars Key Players Head office and Area Served
  • 3.6 Key Players Retinal Biosimilars Product Solution and Service
  • 3.7 Date of Enter into Retinal Biosimilars Market
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 Retinal Biosimilars Breakdown Data by Type

  • 4.1 Global Retinal Biosimilars Historic Market Size by Type (2016-2021)
  • 4.2 Global Retinal Biosimilars Forecasted Market Size by Type (2022-2027)

5 Retinal Biosimilars Breakdown Data by Application

  • 5.1 Global Retinal Biosimilars Historic Market Size by Application (2016-2021)
  • 5.2 Global Retinal Biosimilars Forecasted Market Size by Application (2022-2027)

6 North America

  • 6.1 North America Retinal Biosimilars Market Size (2016-2027)
  • 6.2 North America Retinal Biosimilars Market Size by Type
    • 6.2.1 North America Retinal Biosimilars Market Size by Type (2016-2021)
    • 6.2.2 North America Retinal Biosimilars Market Size by Type (2022-2027)
    • 6.2.3 North America Retinal Biosimilars Market Size by Type (2016-2027)
  • 6.3 North America Retinal Biosimilars Market Size by Application
    • 6.3.1 North America Retinal Biosimilars Market Size by Application (2016-2021)
    • 6.3.2 North America Retinal Biosimilars Market Size by Application (2022-2027)
    • 6.3.3 North America Retinal Biosimilars Market Size by Application (2016-2027)
  • 6.4 North America Retinal Biosimilars Market Size by Country
    • 6.4.1 North America Retinal Biosimilars Market Size by Country (2016-2021)
    • 6.4.2 North America Retinal Biosimilars Market Size by Country (2022-2027)
    • 6.4.3 United States
    • 6.4.3 Canada

7 Europe

  • 7.1 Europe Retinal Biosimilars Market Size (2016-2027)
  • 7.2 Europe Retinal Biosimilars Market Size by Type
    • 7.2.1 Europe Retinal Biosimilars Market Size by Type (2016-2021)
    • 7.2.2 Europe Retinal Biosimilars Market Size by Type (2022-2027)
    • 7.2.3 Europe Retinal Biosimilars Market Size by Type (2016-2027)
  • 7.3 Europe Retinal Biosimilars Market Size by Application
    • 7.3.1 Europe Retinal Biosimilars Market Size by Application (2016-2021)
    • 7.3.2 Europe Retinal Biosimilars Market Size by Application (2022-2027)
    • 7.3.3 Europe Retinal Biosimilars Market Size by Application (2016-2027)
  • 7.4 Europe Retinal Biosimilars Market Size by Country
    • 7.4.1 Europe Retinal Biosimilars Market Size by Country (2016-2021)
    • 7.4.2 Europe Retinal Biosimilars Market Size by Country (2022-2027)
    • 7.4.3 Germany
    • 7.4.4 France
    • 7.4.5 U.K.
    • 7.4.6 Italy
    • 7.4.7 Russia
    • 7.4.8 Nordic

8 Asia-Pacific

  • 8.1 Asia-Pacific Retinal Biosimilars Market Size (2016-2027)
  • 8.2 Asia-Pacific Retinal Biosimilars Market Size by Type
    • 8.2.1 Asia-Pacific Retinal Biosimilars Market Size by Type (2016-2021)
    • 8.2.2 Asia-Pacific Retinal Biosimilars Market Size by Type (2022-2027)
    • 8.2.3 Asia-Pacific Retinal Biosimilars Market Size by Type (2016-2027)
  • 8.3 Asia-Pacific Retinal Biosimilars Market Size by Application
    • 8.3.1 Asia-Pacific Retinal Biosimilars Market Size by Application (2016-2021)
    • 8.3.2 Asia-Pacific Retinal Biosimilars Market Size by Application (2022-2027)
    • 8.3.3 Asia-Pacific Retinal Biosimilars Market Size by Application (2016-2027)
  • 8.4 Asia-Pacific Retinal Biosimilars Market Size by Region
    • 8.4.1 Asia-Pacific Retinal Biosimilars Market Size by Region (2016-2021)
    • 8.4.2 Asia-Pacific Retinal Biosimilars Market Size by Region (2022-2027)
    • 8.4.3 China
    • 8.4.4 Japan
    • 8.4.5 South Korea
    • 8.4.6 Southeast Asia
    • 8.4.7 India
    • 8.4.8 Australia

9 Latin America

  • 9.1 Latin America Retinal Biosimilars Market Size (2016-2027)
  • 9.2 Latin America Retinal Biosimilars Market Size by Type
    • 9.2.1 Latin America Retinal Biosimilars Market Size by Type (2016-2021)
    • 9.2.2 Latin America Retinal Biosimilars Market Size by Type (2022-2027)
    • 9.2.3 Latin America Retinal Biosimilars Market Size by Type (2016-2027)
  • 9.3 Latin America Retinal Biosimilars Market Size by Application
    • 9.3.1 Latin America Retinal Biosimilars Market Size by Application (2016-2021)
    • 9.3.2 Latin America Retinal Biosimilars Market Size by Application (2022-2027)
    • 9.3.3 Latin America Retinal Biosimilars Market Size by Application (2016-2027)
  • 9.4 Latin America Retinal Biosimilars Market Size by Country
    • 9.4.1 Latin America Retinal Biosimilars Market Size by Country (2016-2021)
    • 9.4.2 Latin America Retinal Biosimilars Market Size by Country (2022-2027)
    • 9.4.3 Mexico
    • 9.4.4 Brazil

10 Middle East & Africa

  • 10.1 Middle East & Africa Retinal Biosimilars Market Size (2016-2027)
  • 10.2 Middle East & Africa Retinal Biosimilars Market Size by Type
    • 10.2.1 Middle East & Africa Retinal Biosimilars Market Size by Type (2016-2021)
    • 10.2.2 Middle East & Africa Retinal Biosimilars Market Size by Type (2022-2027)
    • 10.2.3 Middle East & Africa Retinal Biosimilars Market Size by Type (2016-2027)
  • 10.3 Middle East & Africa Retinal Biosimilars Market Size by Application
    • 10.3.1 Middle East & Africa Retinal Biosimilars Market Size by Application (2016-2021)
    • 10.3.2 Middle East & Africa Retinal Biosimilars Market Size by Application (2022-2027)
    • 10.3.3 Middle East & Africa Retinal Biosimilars Market Size by Application (2016-2027)
  • 10.4 Middle East & Africa Retinal Biosimilars Market Size by Country
    • 10.4.1 Middle East & Africa Retinal Biosimilars Market Size by Country (2016-2021)
    • 10.4.2 Middle East & Africa Retinal Biosimilars Market Size by Country (2022-2027)
    • 10.4.3 Turkey
    • 10.4.4 Saudi Arabia
    • 10.4.5 UAE

11 Key Players Profiles

  • 11.1 Novartis (Sandoz)
    • 11.1.1 Novartis (Sandoz) Company Details
    • 11.1.2 Novartis (Sandoz) Business Overview
    • 11.1.3 Novartis (Sandoz) Retinal Biosimilars Introduction
    • 11.1.4 Novartis (Sandoz) Revenue in Retinal Biosimilars Business (2016-2021)
    • 11.1.5 Novartis (Sandoz) Recent Development
  • 11.2 Takeda
    • 11.2.1 Takeda Company Details
    • 11.2.2 Takeda Business Overview
    • 11.2.3 Takeda Retinal Biosimilars Introduction
    • 11.2.4 Takeda Revenue in Retinal Biosimilars Business (2016-2021)
    • 11.2.5 Takeda Recent Development
  • 11.3 Bayer
    • 11.3.1 Bayer Company Details
    • 11.3.2 Bayer Business Overview
    • 11.3.3 Bayer Retinal Biosimilars Introduction
    • 11.3.4 Bayer Revenue in Retinal Biosimilars Business (2016-2021)
    • 11.3.5 Bayer Recent Development
  • 11.4 Genentech
    • 11.4.1 Genentech Company Details
    • 11.4.2 Genentech Business Overview
    • 11.4.3 Genentech Retinal Biosimilars Introduction
    • 11.4.4 Genentech Revenue in Retinal Biosimilars Business (2016-2021)
    • 11.4.5 Genentech Recent Development
  • 11.5 Pfenex
    • 11.5.1 Pfenex Company Details
    • 11.5.2 Pfenex Business Overview
    • 11.5.3 Pfenex Retinal Biosimilars Introduction
    • 11.5.4 Pfenex Revenue in Retinal Biosimilars Business (2016-2021)
    • 11.5.5 Pfenex Recent Development
  • 11.6 Reliance Life Sciences
    • 11.6.1 Reliance Life Sciences Company Details
    • 11.6.2 Reliance Life Sciences Business Overview
    • 11.6.3 Reliance Life Sciences Retinal Biosimilars Introduction
    • 11.6.4 Reliance Life Sciences Revenue in Retinal Biosimilars Business (2016-2021)
    • 11.6.5 Reliance Life Sciences Recent Development
  • 11.7 Hetero Drugs
    • 11.7.1 Hetero Drugs Company Details
    • 11.7.2 Hetero Drugs Business Overview
    • 11.7.3 Hetero Drugs Retinal Biosimilars Introduction
    • 11.7.4 Hetero Drugs Revenue in Retinal Biosimilars Business (2016-2021)
    • 11.7.5 Hetero Drugs Recent Development
  • 11.8 Intas Pharmaceuticals
    • 11.8.1 Intas Pharmaceuticals Company Details
    • 11.8.2 Intas Pharmaceuticals Business Overview
    • 11.8.3 Intas Pharmaceuticals Retinal Biosimilars Introduction
    • 11.8.4 Intas Pharmaceuticals Revenue in Retinal Biosimilars Business (2016-2021)
    • 11.8.5 Intas Pharmaceuticals Recent Development
  • 11.9 Santo Holding
    • 11.9.1 Santo Holding Company Details
    • 11.9.2 Santo Holding Business Overview
    • 11.9.3 Santo Holding Retinal Biosimilars Introduction
    • 11.9.4 Santo Holding Revenue in Retinal Biosimilars Business (2016-2021)
    • 11.9.5 Santo Holding Recent Development
  • 11.10 Regeneron Pharmaceuticals
    • 11.10.1 Regeneron Pharmaceuticals Company Details
    • 11.10.2 Regeneron Pharmaceuticals Business Overview
    • 11.10.3 Regeneron Pharmaceuticals Retinal Biosimilars Introduction
    • 11.10.4 Regeneron Pharmaceuticals Revenue in Retinal Biosimilars Business (2016-2021)
    • 11.10.5 Regeneron Pharmaceuticals Recent Development

12 Analyst's Viewpoints/Conclusions

    13 Appendix

    • 13.1 Research Methodology
      • 13.1.1 Methodology/Research Approach
      • 13.1.2 Data Source
    • 13.2 Disclaimer

    Retinal Biosimilars market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Retinal Biosimilars market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

    Segment by Type
    Macular Degeneration Drugs
    Diabetic Eye Disease Drugs
    Macular Pucker Drugs
    Others

    Segment by Application
    Hospital Pharmacies
    Retail Pharmacies
    Online Pharmacies

    By Region
    North America
    U.S.
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Nordic
    Rest of Europe
    Asia-Pacific
    China
    Japan
    South Korea
    Southeast Asia
    India
    Australia
    Rest of Asia
    Latin America
    Mexico
    Brazil
    Rest of Latin America
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE
    Rest of MEA

    By Company
    Novartis (Sandoz)
    Takeda
    Bayer
    Genentech
    Pfenex
    Reliance Life Sciences
    Hetero Drugs
    Intas Pharmaceuticals
    Santo Holding
    Genentech

    Buy now